Skip to main content

Advertisement

Table 1 Characteristics of the study population

From: A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

Numerical variables all patients ART-naive ART-experienced
   median (IQR) median (IQR) median (IQR)
calendar year 2004 (2003-2006) 2006 (2004-2007) 2004 (2002-2005)
HIV-1 RNA log10 copies/ml 4.53 (3.83-5.12) 5.08 (4.63-5.5) 4.18 (3.63-4.8)
CD4+ count cells/mm3 273 (147-389) 191 (70-300) 296.8 (192-435)
Age years 40 (36-45) 39 (33-45) 40 (37-45)
GSS Rega 3 (2-3) 3 (3-3) 2 (1.5-3)
  ANRS 3 (2-3) 3 (3-3) 2 (1.5-3)
  HIVdb 3 (2-3) 3 (3-3) 2 (1.5-3)
Categorical variables n (%) n (%) n (%)
#patients 2158 733 (34.0%) 1425 (57.7%)
#cART regimens 2337 733 (31.4%) 1604 (68.6%)
cART type 2NRTI+1NNRTI 516 (23.9%) 235 (32.1%) 281 (19.7%)
  2NRTI+1PI 243 (11.3%) 45 (6.1%) 198 (13.9%)
  2NRTI+1PI/r 1306 (60.5%) 441 (60.2%) 865 (60.7%)
  3NRTI 93 (4.3%) 12 (1.6%) 81 (5.7%)
gender male 1546 (71.6%) 563 (76.8%) 983 (69%)
previous AIDS-defining events (yes vs. no) 285 (13.2%) 92 (12.6%) 193 (13.5%)
Nationality Italian 1524 (70.6%) 529 (72.2%) 995 (69.8%)
  non-Italian 168 (7.8%) 98 (13.4%) 70 (4.9%)
  unknown 466 (21.6%) 106 (14.5%) 360 (25.3%)
mode of HIV-1 transmission heterosexual 657 (30.4%) 262 (35.7%) 395 (27.7%)
  male homosexual 362 (16.8%) 154 (21%) 208 (14.6%)
  IDU 468 (21.7%) 54 (7.4%) 414 (29.1%)
  other/unknown 671 (31.1%) 263 (35.9%) 408 (28.6%)
HBV/HCV co-infection positive 605 (28%) 149 (20.3%) 456 (32%)
  negative 483 (22.4%) 260 (35.5%) 223 (15.6%)
  unknown 1070 (49.6%) 324 (44.2%) 746 (52.4%)
interval time from the first HIV-1 positive test to cART initiation < = 12 months 444 (20.6%) 354 (48.3%) 90 (6.3%)
  > 12 and < = 60 months 188 (8.7%) 45 (6.1%) 143 (10%)
  > 60 months 575 (26.6%) 61 (8.3%) 514 (36.1%)
  unknown 951 (44.1%) 273 (37.2%) 678 (47.6%)
duration of prior ART exposures < = 6 months 1197 (55.5%) 733 (100%) 464 (32.6%)
  > 6 and < = 12 months 117 (5.4%) N/A 117 (8.2%)
  > 12 and < = 24 months 184 (8.5%) N/A 184 (12.9%)
  > 24 months 660 (30.6%) N/A 660 (46.3%)
viral subtype B 1753 (81.2%) 503 (68.6%) 1250 (87.7%)
  02_AG 56 (2.6%) 28 (3.8%) 28 (2%)
  C 41 (1.9%) 31 (4.2%) 10 (0.7%)
  F1 54 (2.5%) 39 (5.3%) 15 (1.1%)
  other 60 (2.8%) 35 (4.8%) 25 (1.8%)
  undetermined 194 (9%) 97 (13.2%) 97 (6.8%)
#previous ART switches none 733 (34%) 733 (100%) N/A
  one/two 429 (19.9%) N/A 429 (30.1%)
  three to six 605 (28%) N/A 605 (42.5%)
  more than six 391 (18.1%) N/A 391 (27.4%)
previous exposure to suboptimal ART (yes vs. no) 922 (42.7%) N/A 922 (64.7%)
previous ART class exposure none 733 (34%) 733 (100%) N/A
  only NRTI 94 (4.4%) N/A 94 (6.6%)
  NRTI and NNRTI 220 (10.2%) N/A 220 (15.4%)
  NRTI, NNRTI and PI 252 (11.7%) N/A 252 (17.7%)
  NRTI, NNRTI and PI/r 466 (21.6%) N/A 466 (32.7%)
  NRTI and PI 229 (10.6%) N/A 229 (16.1%)
  NRTI and PI/r 134 (6.2%) N/A 134 (9.4%)
  other classes 30 (1.4%) N/A 30 (2.1%)
  1. *cART: combination antiretroviral therapy; GSS: genotypic susceptibility score; ART: antiretroviral therapy; NRTI: nucleoside/tide reverse transcriptase inhibitors; NNRTI: non-nucloeside reverse transcriptase inhibitors; PI: protease inhibitors; IDU: injecting drug users; HCV: hepatitis C virus; HBV: hepatitis B virus.